| Name | Title | Contact Details |
|---|
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
BioTek Instruments is a worldwide leader in the development of high performance, bioanalytical measurement systems and software. Our representatives worldwide call on a variety of customers including academic, government, and biotech/pharmaceutical. We